Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Illumina Laboratory Services, |
RCV001115329 | SCV001273298 | uncertain significance | Retinitis pigmentosa 37 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Illumina Laboratory Services, |
RCV001121911 | SCV001280566 | uncertain significance | Enhanced S-cone syndrome | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Labcorp Genetics |
RCV001247193 | SCV001420601 | pathogenic | not provided | 2024-05-15 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 309 of the NR2E3 protein (p.Arg309Trp). This variant is present in population databases (rs774102273, gnomAD 0.005%). This missense change has been observed in individual(s) with clinical features of enhanced S-cone syndrome and/or Goldmann-Favre syndrome (PMID: 33781268; Invitae). ClinVar contains an entry for this variant (Variation ID: 884317). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt NR2E3 protein function with a positive predictive value of 80%. This variant disrupts the p.Arg309 amino acid residue in NR2E3. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 10655056, 15459973, 19718767; Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
Natera, |
RCV001121911 | SCV002085630 | uncertain significance | Enhanced S-cone syndrome | 2020-04-15 | no assertion criteria provided | clinical testing |